Liquidia Technologies Inc (LQDA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Liquidia Technologies Inc (LQDA) has a cash flow conversion efficiency ratio of 0.488x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($52.99 Million) by net assets ($108.58 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Check Liquidia Technologies Inc (LQDA) strategic investment index to assess the company's strategic physical and investment asset allocation.
Liquidia Technologies Inc - Cash Flow Conversion Efficiency Trend (2016–2025)
This chart illustrates how Liquidia Technologies Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. See what is Liquidia Technologies Inc's book value for net asset value and shareholders' equity analysis.
Liquidia Technologies Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Liquidia Technologies Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Compagnie Generale des Etablissements Michelin SCA
LSE:0OFM
|
0.069x |
|
Valmet Oyj
HE:VALMT
|
0.038x |
|
Red Avenue New Materials Group Co Ltd
SHG:603650
|
0.058x |
|
Enstar Group Limited
NASDAQ:ESGR
|
0.023x |
|
Parkland Fuel Corporation
TO:PKI
|
0.158x |
|
INPOST S.A. EO -01
F:669
|
N/A |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
-0.026x |
|
Sk Biopharmaceuticals Co Ltd
KO:326030
|
0.105x |
Annual Cash Flow Conversion Efficiency for Liquidia Technologies Inc (2016–2025)
The table below shows the annual cash flow conversion efficiency of Liquidia Technologies Inc from 2016 to 2025. For the full company profile with market capitalisation and key ratios, see Liquidia Technologies Inc market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $44.75 Million | $-35.69 Million | -0.797x | +34.03% |
| 2024-12-31 | $77.28 Million | $-93.42 Million | -1.209x | -37.56% |
| 2023-12-31 | $47.29 Million | $-41.56 Million | -0.879x | -177.98% |
| 2022-12-31 | $90.42 Million | $-28.59 Million | -0.316x | +39.37% |
| 2021-12-31 | $65.27 Million | $-34.03 Million | -0.521x | +31.53% |
| 2020-12-31 | $71.09 Million | $-54.14 Million | -0.762x | +44.87% |
| 2019-12-31 | $34.95 Million | $-48.28 Million | -1.382x | +18.89% |
| 2018-12-31 | $18.69 Million | $-31.83 Million | -1.703x | -336.26% |
| 2017-12-31 | $-33.69 Million | $-24.29 Million | 0.721x | -5.68% |
| 2016-12-31 | $-18.25 Million | $-13.95 Million | 0.764x | -- |
About Liquidia Technologies Inc
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for rare cardiopulmonary diseases in the United States. The company's lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung diseas… Read more